For lymphoma patients, there are a variety of potential targets, such as T-cell markers (CD3, CD4, and CD8), B-cell markers (CD19 or CD20), and immune checkpoints (PD-1, PD-L1, or CTLA-4) [28]. This evidence concerns the gene CD274 and lymphoma.